Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/13/1222   
Active ingredient: Amatuximab
Indication: Treatment of malignant mesothelioma
Sponsor: Eisai Europe Limited
European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/01/2014 Orphan designation EMA/OD/108/13 (2014)292 of 16/01/2014